Neuroblastoma Therapeutic Market Poised to Grow Considerably owing to High Incidence of Neuroblastoma Disease

 

Neuroblastoma is a type of cancer that forms in certain types of nerve cells (neuroblasts) found in an embryonic tissue called the neural crest. It most commonly forms in the adrenal glands, abdomen or chest. The global neuroblastoma therapeutic market is primarily driven by the increasing incidence of neuroblastoma disease globally. Neuroblastoma therapeutics occurs in around 1 in 100,000 children per year, making it one of the most common cancers in babies and young children. The primary treatment for neuroblastoma involves chemotherapy, surgery, radiation therapy, stem cell transplant and immunotherapy. Key therapeutic options include chemotherapy drugs like carboplatin, etoposide, cyclophosphamide; targeted therapies like dinutuximab and anti-GD2 antibody; and other novel drugs.

The Global Neuroblastoma Therapeutic Market is estimated to be valued at US$ 2.78 Bn in 2024 and is expected to exhibit a CAGR of 6.9% over the forecast period 2024 To 2031.

Key Takeaways
Key players operating in the neuroblastoma therapeutic market are United Therapeutics, Apeiron Biologics AG, Baxter, and Pfizer. They are investing aggressively in developing novel therapeutics to improve outcomes in neuroblastoma patients.

The growing incidence of neuroblastoma therapeutics disease globally is a major factor driving the demand for effective treatment options. According to statistics, neuroblastoma accounts for around 15% of all cancer deaths among children. This has fueled the need for advanced targeted therapies and immunotherapies.

Technological advancements are revolutionizing the treatment landscape. Several pharmaceutical companies are engaged in research & development of monoclonal antibodies, antibody-drug conjugates, cancer vaccines and other targeted therapies to achieve better survival rates. Promising immunotherapies like ch14.18/CHO (Dinutuximab), anti-GD2 antibody and naxitamab are being evaluated in clinical trials.

Market Trends
Personalized medicine is gradually becoming a key trend with companies developing therapies specific to high-risk patient subsets. Biomarkers and genetic testing help determine personalized treatment protocols.

Immunotherapies are gaining popularity for neuroblastoma due to their potential to induce long-term remissions. Chimeric antigen receptor T cell (CAR-T) therapies and checkpoint inhibitors are being actively researched for treatment of relapsed/refractory disease.

Market Opportunities
North America represents a lucrative market opportunity due to conducive regulatory environment and presence of top pharmaceutical companies. The approval of dinutuximab by FDA in 2015 accelerated clinical research in the region.

There is ample scope for developing novel drug combinations involving immunotherapies that can enhance survival rates, especially in high-risk patients. Successful research holds promise to improve clinical outcomes in neuroblastoma.

The COVID-19 pandemic has had a noticeable impact on the growth of the neuroblastoma therapeutic market. There was limited availability of treatments as healthcare facilities focused their resources on COVID patients. This led to diagnostic and screening being postponed or delayed for cancer patients including those with neuroblastoma.

Access to immunotherapies and targeted therapies also became difficult during the peak of the pandemic. Supply chain disruptions further constrained the availability of critical medicines. Clinical trials too had to be halted or delayed which impacted new drug development efforts. Telehealth and digital health solutions helped to some extent in continuing care for stable patients virtually.

Going forward, as the pandemic is brought under control, focus needs to return towards cancer care. Appropriate screening and early diagnosis will need to be ramped up quickly. Ensuring uninterrupted supply of existing therapeutics through strategic partnerships is important. New innovative treatment approaches in the pipeline also need to progress on schedule through renewed clinical research.

In terms of value, North America currently contributes the largest share to the neuroblastoma therapeutic market owing to developed healthcare infrastructure and high treatment costs. However, Asia Pacific is emerging as the fastest growing regional market. This is driven by increasing awareness, better access to modern therapies and rising healthcare investments across countries like China and India.

Get more insights on : https://justpaste.it/fjy54

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)